US0044685008
US0044685008
Achieve Life Sciences, Inc.
Loading chart...
Company Profile
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Latest News

GlobeNewswire • 10/07/2026
Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications

GlobeNewswire • 10/06/2026
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
MT Newswires • 10/01/2026
Achieve Life Sciences Names Benjamin Halladay CFO

GlobeNewswire • 10/01/2026
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
MT Newswires • 09/30/2026
Stifel Initiates Achieve Life Sciences at Buy With $18 Price Target
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
Company Profile
5
MetricsCountry
Region
Sector
Industry
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data
7/7 Very High
5Y Volatility
74.3% p.a.
Max Drawdown (5Y)
-80.1%
Sharpe Ratio (5Y)
-0.07
Beta Factor
2.31
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
High market risk: Beta of 2.31 indicates above-average volatility compared to the broader market.
Elevated Short-Term Volatility: 3Y volatility (79.9%) is noticeably higher than the 5Y average (74.3%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (74.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.9% in the extended horizon.